EphA4/Tie2 crosstalk regulates leptomeningeal collateral remodeling following ischemic stroke

Benjamin Okyere, … , John B. Matson, Michelle H. Theus


Leptomeningeal anastomoses or pial collateral vessels play a critical role in cerebral blood flow (CBF) restoration following ischemic stroke. The magnitude of this adaptive response is postulated to be controlled by the endothelium, although the underlying molecular mechanisms remain under investigation. Here we demonstrated that endothelial genetic deletion, using *EphA4*fl/fl/Tie2-Cre and *EphA4*fl/fl/VeCahderin-CreERT2 mice and vessel painting strategies, implicated EphA4 receptor tyrosine kinase as a major suppressor of pial collateral remodeling, CBF, and functional recovery following permanent middle cerebral artery occlusion. Pial collateral remodeling is limited by the crosstalk between EphA4-Tie2 signaling in vascular endothelial cells, which is mediated through p-Akt regulation. Furthermore, peptide inhibition of EphA4 resulted in acceleration of the pial arteriogenic response. Our findings demonstrate that EphA4 is a negative regulator of Tie2 receptor signaling, which limits pial collateral arteriogenesis following cerebrovascular occlusion. Therapeutic targeting of EphA4 and/or Tie2 represents an attractive new strategy for improving collateral function, neural tissue health, and functional recovery following ischemic stroke.

Find the latest version:

https://jci.me/131493/pdf
EphA4/Tie2 crosstalk regulates leptomeningeal collateral remodeling following ischemic stroke

Benjamin Okyere,1 William A. Mills III,2,3 Xia Wang,1 Michael Chen,1 Jiang Chen,1 Amanda Hazy,1 Yun Qian,4,5 John B. Matson,4,6 and Michelle H. Theus1,2,7

1Department of Biomedical Sciences and Pathobiology, 2School of Neuroscience, 3Graduate Program in Translational Biology, Medicine, and Health, 4Department of Mechanical Engineering, 5Center for Drug Discovery, 6Department of Chemistry, and 7Center for Regenerative Medicine, College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, USA.

Introduction
Ischemic stroke results in significant cerebral blood flow (CBF) loss to brain regions predominately served by the middle cerebral artery, leading to cell death and neural tissue dysfunction. However, restoration of CBF may occur through developmentally regulated adaptations to the vascular network called leptomeningeal anastomoses or pial collateral vessels, which provide retrograde reperfusion to vulnerable tissue regions. This phenomenon is essential for preventing or reducing the consequences of an ischemic attack; however, the molecular mechanism(s) regulating the patient-specific pial collateral response remains understudied. While tissue plasminogen activator (tPA) and/or Alteplase remains the gold standard for stroke therapy, it is not effective in large vessel occlusions (LVOs) or when treatment is started prior to 4.5 hours after ischemic attack (1, 2) or 9 hours after ischemic attack in selected patients (3). Recently, the use of endovascular thrombectomy (3). Recently, we implicated EphA4 receptor tyrosine kinase in limiting pial collateral arteriogenesis following permanent middle cerebral artery occlusion. Pial collateral remodeling is limited by the crosstalk between EphA4-Tie2 signaling in vascular endothelial cells, which is mediated through p-Akt regulation. Furthermore, peptide inhibition of EphA4 resulted in acceleration of the pial arteriogenic response. Our findings demonstrate that EphA4 is a negative regulator of Tie2 receptor signaling, which limits pial collateral arteriogenesis following cerebral occlusion. Therapeutic targeting of EphA4 and/or Tie2 represents an attractive new strategy for improving collateral function, neural tissue health, and functional recovery following ischemic stroke.

The extent of collateral-mediated reperfusion has a major impact on preserving the penumbra and often dictates stroke outcome (9–13). Several studies have demonstrated that the outcome after thrombolysis and thrombectomy therapy is highly dependent on patient collateral scoring (14–19). Patients with high collateral function also have higher reperfusion rates after tPA therapy and a lower risk for symptomatic bleeding after reperfusion therapy (20). Pharmacological targeting of the pial collateral network therefore represents a viable therapeutic option to improve outcomes following embolic stroke, by sustaining penumbral blood flow and preserving neural tissue health. The middle cerebral arteries (MCAs), anterior cerebral arteries (ACAs), and posterior cerebral arteries (PCAs) Anastomose at their distal ends to form the MCA-ACA and MCA-PCA collateral vessels (21). Collateral vessels do not show a proximal-to-distal axis with respect to blood flow, rather they connect 2 arterial branches with opposing flow. Therefore, collateral blood flow is bidirectional along the collateral vessel wall (22). Following an obstruction, collateral vessels undergo immense vascular restructuring and remodeling (enlargement), also called arteriogenesis, to allow for unidirectional retrograde blood reperfusion into the area of an occluded arterial branch (22, 23).

Although the benefits of targeting the collateral system are evident, further research is essential to elucidate the mechanism(s) underlying this remarkable tissue-saving adaptation. Collateral remodeling is initiated when mechanoreceptors on endothelial cells (ECs) detect fluid shear stress after an occlusion (24–26). Thus, the ECs comprised within the collateral niche may perform essential duties during the active remodeling process. Recently, we implicated EphA4 receptor tyrosine kinase in lim-
CBF was measured by laser doppler prior to and at 5 minutes, then again 1–4 days after pMCAO in the ipsilateral hemisphere. The perfusion units (PFUs) were quantified and are represented relative to baseline preinjury CBF (Figure 1, A and B). No significant difference in CBF was observed at 5 minutes after pMCAO between WT and KO mice (relative PFUs: 0.532 ± 0.026 vs. 0.502 ± 0.034). However, we observed a significant increase in CBF at 1 day (0.87 ± 0.05 vs. 0.69 ± 0.05), 2 days (0.94 ± 0.06 vs. 0.73 ± 0.05), 3 days (0.95 ± 0.05 vs. 0.79 ± 0.06), and 4 days (0.97 ± 0.04 vs. 0.82 ± 0.04) in KO mice compared with WT mice. These findings correlated with reduced infarct volume in KO mice (15.57 ± 3.26 mm³) compared with WT mice (26.77 ± 3.13 mm³) at 4 days after pMCAO (Figure 1, C–E). Likewise, we found that KO mice showed improvements in behavioral recovery. Rotarod assessment demonstrated a significant increase in motor function in KO compared with WT mice at 7 days and increased trend at 3 days and 14 days after pMCAO (Figure 1F). While increased neurological severity scoring was observed following pMCAO, no significant difference was found between WT and KO mice (Figure 1G). However, assessment using novel

Results

EphA4fl/fl/Tie2-Cre knockout mice show improved CBF, neural tissue, and behavioral recovery following permanent middle cerebral artery occlusion (pMCAO). In the current study, we used EphA4fl/fl/Tie2-Cre knockout (KO) mice to evaluate changes in CBF following acute ischemic stroke and subsequent outcomes compared with EphA4fl/fl WT mice. Vascular recombination was confirmed using Tie2-Cre/ROSA²6Cre reporter mice (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI131493DS1) and as previously described (27). CBF was measured by laser doppler prior to and at 5 minutes, then again 1–4 days after pMCAO in the ipsilateral hemisphere. The perfusion units (PFUs) were quantified and are represented relative to baseline preinjury CBF (Figure 1, A and B). No significant difference in CBF was observed at 5 minutes after pMCAO between WT and KO mice (relative PFUs: 0.532 ± 0.026 vs. 0.502 ± 0.034). However, we observed a significant increase in CBF at 1 day (0.87 ± 0.05 vs. 0.69 ± 0.05), 2 days (0.94 ± 0.06 vs. 0.73 ± 0.05), 3 days (0.95 ± 0.05 vs. 0.79 ± 0.06), and 4 days (0.97 ± 0.04 vs. 0.82 ± 0.04) in KO mice compared with WT mice. These findings correlated with reduced infarct volume in KO mice (15.57 ± 3.26 mm³) compared with WT mice (26.77 ± 3.13 mm³) at 4 days after pMCAO (Figure 1, C–E). Likewise, we found that KO mice showed improvements in behavioral recovery. Rotarod assessment demonstrated a significant increase in motor function in KO compared with WT mice at 7 days and increased trend at 3 days and 14 days after pMCAO (Figure 1F). While increased neurological severity scoring was observed following pMCAO, no significant difference was found between WT and KO mice (Figure 1G). However, assessment using novel
Figure 2. Increased collateral remodeling in EC-specific KO mice after pMCAO. (A and B) Vessel painted WT brain 1 day after pMCAO showing pial collateral vessels (arrows) in the ipsilateral hemisphere. (C and D) KO vessel painted brain 1 day after pMCAO. (E) MCA-ACA collateral diameter analyses 1 and 4 days after pMCAO. KO mice show increased collateral size compared with WT mice (*). Ipsilateral collaterals are larger in diameter compared with contralateral at both time points (#). Ipsilateral vessels 4 days after injury are significantly larger than 1 day after injury in both genotypes ($). (F) MCA-PCA collateral analyses 1 and 4 days after stroke. (G) Average inter-collateral analyses and (H) inter-collateral counts show no significant difference between time points or between ipsilateral and contralateral hemispheres. Breakdown of collateral vessel size at 1 day (I) and 4 days (J) after pMCAO. One-way ANOVA with Bonferroni’s post hoc test; n = 7–10 per group. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Scale bars in A–D: 1 mm.
MCA-PCA combined showed an increase in KO mice compared to WT mice (collaterals between the main branches of the MCA-ACA and MCA-PCA) 2.15 ± 1.20 μm, respectively) and 4 days (50.43 ± 2.83 μm vs. 37.72 ± 1.88 μm vs. 26.90 μm) after pMCAO. Enhanced remodeling of MCA-ACA inter-collaterals 1 day (KO 53.29 ± 41.08 μm vs. WT 29.59 ± 1.79 μm) and 4 days (KO 52% compared with 18% in WT mice (Figure 2, I and J).}

**Figure 3. Increased cell proliferation within the MCA-ACA collateral niche of KO mice 1 day after pMCAO.** Vessel painted brains were immuno-labeled with anti-PCNA (green; white arrows) and imaged by high magnification confocal imaging. Maximum Z-projection analysis of the entire Z-stacked vessel was used to assess cell division for evidence of collateral remodeling as early as 1 day after pMCAO in the ipsilateral (A–E) and contralateral (F and G) hemispheres. (A) Representative 3D projected image from vessel painted (red) ipsilateral KO pial surface of an MCA-ACA collateral colabeled with antibodies against PCNA. KO collateral vessels show a greater number of PCNA+ cells aligned within (elongated compared with surrounding PCNA+ cells) the vessel territory of the occluded MCAs, we also evaluated those inter-collaterals. MCA-PCA also showed increased collateral diameter between groups or in the total number of inter-collaterals (Figure 2H) after pMCAO, suggesting that EphA4 improved CBF through collateral remodeling rather than having greater numbers to begin with, which was confirmed by the total number of inter-collateral counts. Moreover, breakdown of collateral size shows that the largest increase in collateral diameter occurred in the ipsilateral KO mice, where 85% of collaterals were greater than 31 μm at 1 day and 91% at 4 days after pMCAO, compared with 10%–15% on the contralateral side. Conversely, 40% of the WT ipsilateral collaterals were greater than 31 μm at 1 day and 75% at 4 days after pMCAO. Additionally, a greater number of KO collaterals were larger than 50 μm: 52% compared with 18% in WT mice (Figure 2, I and J).

Given Tie2 may also be expressed by a subset of immune cells, we further validated the cell-autonomous role of EC-specific EphA4 in pial collateral remodeling by utilizing an inducible Cre system. We first tested the utility of Tie2-CreERT2 versus VcCadherin-CreERT2 mice using a reporter system and found that, 2 weeks after 5 consecutive injections of 2 mg/kg/day tamoxifen, VcCadherin-CreERT2/Rosa26tmG mice showed complete recombination, whereas Tie2-CreERT2/Rosa26tmG showed incomplete recombination (Supplemental Figure 2, A–F). This was true even at object recognition (NOR) showed that pMCAO reduced the novel object preference index in WT but not KO mice at 3 days (62.75 ± 1.08 vs. 45.58 ± 2.61), 7 days (63.81 ± 2.57 vs. 50.01 ± 1.68), and 14 days (69.42 ± 3.15 vs. 50.16 ± 0.87) (Figure 1H). These findings demonstrate that EC-specific EphA4 is a mediator of functional deficits and neural tissue damage following pMCAO.

**Figure 3.**}
3 mg/kg/day (data not shown). We then analyzed collateral diameters 1 day after pMCAO in tamoxifen-treated EphA4^{fl/fl} (iWT) and EphA4^{fl/fl}/VeCadherin-CreERT2 (iKO) mice and found a significant increase in ipsilateral pial size in iKO mice compared with iWT mice (Supplemental Figure 2, G–I). These findings demonstrate that loss of EC-specific EphA4 can accelerate pial arteriogenesis as early as 24 hours after pMCAO.

Evidence of early cellular remodeling in EphA4^{fl/fl}/Tie2-Cre vessel painted MCA-ACA collaterals. EphA4 suppresses EC proliferation in vitro (27) and the pial collateral niche undergoes active cellular remodeling following pMCAO (28). To address whether the loss of EC-specific EphA4 improved early remodeling of pial vessels by enhancing EC growth properties, we performed immunolabeling for cell division marker, PCNA on wild type and KO cortical tissue whole mounts 1 day after pMCAO and vessel painting. Maximum Z-projected confocal image analysis shows KO mice (Figure 3, A–C) displayed a greater number of PCNA+ cells in the MCA-ACA pial ipsilateral collateral vessel wall (Figure 3, I–K) compared with WT ipsilateral and KO contralateral vessels (Figure 3, D–H). These findings suggest EphA4 may limit early remodeling, in part, by suppressing EC proliferation in the collateral niche.

EphA4^{fl/fl}/Tie2-Cre mice display increased p-Akt and Angpt2 cortical expression after pMCAO. To test whether Tie2-specific deletion of EphA4 could influence p-Akt/Angpt pathways after stroke, we assessed the protein lysates derived from the ipsilateral cortex 1 day and 4 days after pMCAO in EphA4^{fl/fl} and EphA4^{fl/fl}/Tie2-Cre mice. Using Western blot analysis, we observed a significant decrease in the expression of p-Akt in WT pMCAO-injured cortices compared with WT sham (0.06 ± 0.03 vs. 0.27 ± 0.05, relative to total Akt, respectively). However, the level of p-Akt was maintained in the KO injured cortex compared with sham at 1 day (0.23 ± 0.02 vs. 0.38 ± 0.14, relative to total Akt, respectively) (Figure 4, A and B). No significant change was seen 4 days after pMCAO (Figure 4, C and D). We also evaluated the expression of angiopoietin-1 and -2 (Angpt1, Angpt2) one day after pMCAO and found a significant reduction in Angpt2, exclusively expressed on ECs and a small population of immune cells, in the WT injured cortex compared with sham (0.61 ± 0.10 vs. 1.35 ± 0.13, respectively). This effect was attenuated in KO mice (1.19 ± 0.17 vs. 1.32 ± 0.10, respectively) (Figure 4, E and F). Angpt1 showed no significant difference between samples (Supplemental Figure 3C).

These data reveal that EphA4 suppresses Angpt2 and p-Akt signaling following pMCAO.

Blocking Tie2 receptor prevents collateral remodeling, p-Akt expression, and neuroprotection in EphA4^{fl/fl}/Tie2-Cre mice. To investigate whether the genetic deletion of EC-specific EphA4 enhances collateral remodeling, p-Akt expression, and neuroprotection via Tie2 receptor signaling, we administered 5 mg/kg/day soluble Tie2-Fc or human Fc-control via tail vein injection immediately after pMCAO in EphA4^{fl/fl} and EphA4^{fl/fl}/Tie2-Cre mice. Using Western blot analysis, we observed a significant decrease in the expression of p-Akt in WT pMCAO-injured cortices compared with WT sham (0.06 ± 0.03 vs. 0.27 ± 0.05, relative to total Akt, respectively). However, the level of p-Akt was maintained in the KO injured cortex compared with sham at 1 day (0.23 ± 0.02 vs. 0.38 ± 0.14, relative to total Akt, respectively) (Figure 4, A and B). No significant change was seen 4 days after pMCAO (Figure 4, C and D). We also evaluated the expression of angiopoietin-1 and -2 (Angpt1, Angpt2) one day after pMCAO and found a significant reduction in Angpt2, exclusively expressed on ECs and a small population of immune cells, in the WT injured cortex compared with sham (0.61 ± 0.10 vs. 1.35 ± 0.13, respectively). This effect was attenuated in KO mice (1.19 ± 0.17 vs. 1.32 ± 0.10, respectively) (Figure 4, E and F). Angpt1 showed no significant difference between samples (Supplemental Figure 3C).
Tie2-Cre mice. We observed a significant attenuation of ipsilateral collateral remodeling in KO mice receiving soluble Tie2-Fc (31.84 ± 1.06 μm) compared with Fc-control (41.00 ± 4.80 μm) 1 day after pMCAO. No effect on collateral diameter was found in the ipsilateral hemisphere of WT mice (Figure 5C). Similar changes were seen when comparing MCA-ACA (Figure 5D) and MCA-PCA (Figure 5E). These findings coincided with increased infarct volume in KO mice receiving Tie2-Fc (24.93 ± 3.60 mm³) compared with Fc-control (12.16 ± 3.52 mm³) (Figure 5F and G). Furthermore, blocking Tie2 receptor signaling suppressed p-Akt expression in the cortex of KO mice treated with soluble Tie2-Fc (0.05 ± 0.03, relative to total Akt) compared with Fc-control (0.17 ± 0.02, relative to total Akt) (Figure 5H and I).

EphA4 suppresses Tie2/p-Akt expression to limit EC proliferation in vitro. Collateral remodeling is initiated by the interplay between endothelial cell proliferation and inflammation (29–31). To test whether inflammatory stimuli regulates the expression of EphA4 and Tie2 on the endothelium and to determine whether EphA4 loss-of-function results in differential gene expression, we subjected brain-derived WT and KO ECs (27) to lipopolysaccharide (LPS) for 4 and 24 hours. We confirmed genetic knockout
of EphA4 and showed that LPS stimulation results in a transient reduction in EphA4 and Tier2 at 4 hours and no change at 24 hours in WT ECs (Figure 6A and B). Conversely, KO ECs show a significant increase in Tier2 expression in both vehicle and LPS-treated cells compared with WT ECs at both time points (Figure 6B). In addition, Angpt2, a known mediator of collateral remodeling in hindlimb ischemia (32), is reduced following 4- and 24-hour LPS stimulation in WT ECs, which is greatly enhanced in KO ECs (Figure 6C). To gain insight into the role of EphA4/Tier2 crosstalk on endothelial cell function, we blocked Tier2 signaling in WT and KO ECs using soluble Tier2-Fc and Fc-control, then evaluated proliferation and p-Akt expression. Compared with Fc-control, we found that Tier2-Fc treatment significantly attenuated the enhanced proliferation observed in KO ECs while having no effect on WT ECs in a dose-dependent manner (Figure 6D–F). We previously showed that KO ECs have increased p-Akt expression compared with WT ECs (27). Here we show by Western blot analysis that p-Akt protein expression in KO ECs was reduced following Tier2-Fc treatment (Figure 6G). These data suggest that EphA4 suppresses EC proliferation and Akt signaling by regulating Tier2 expression and function. Last, we found that 87.5 and 106 dyne/cm² shear stress for 4 hours significantly increased mRNA expression of EphA4 in WT ECs (Figure 6H). The WT and KO EC purity was also assessed by qPCR at passage 3 (Figure 3I). Taken together, our in vitro findings suggest that collateral shear stress may upregulate EphA4 expression, leading to suppression of Tier2 signaling and subsequent collateral remodeling (Figure 6I).

Pharmacological inhibition of EphA4 increases collateral remodeling after pMCAO. Finally, we evaluated whether pharmacological inhibition of EphA4 could recapitulate the enhanced collateral remodeling seen in EphA4fl/fl/Tier2-Cre and EphA4fl/fl/VeCadherin-CreERT2 mice. To test this, we utilized sub-Q mini-osmotic pump infusion of the EphA4 peptide inhibitor, KYL, which prevents ligand binding and EphA4 activation (33–35). At 4 days after pMCAO, we observed a significant increase in the ipsilateral pial collateral diameter in KYL-treated mice.
ischemic stroke. Findings from the current study describe a mechanism that restricts outward growth and remodeling. Our results implicate the Tie2-EphA4 axis as a critical regulator of pial collateral remodeling following stroke. The presence of EphA4 on the endothelium acts as a negative cue within the collateral niche to restrict Tie2 receptor function via the p-Akt pathway, thereby restricting collateral outgrowth and remodeling.

**EphA4 fl/fl/Tie2-Cre** mice show increased p-Akt signaling, collateral remodeling, and tissue protection, which were attenuated in the presence of soluble Tie2 inhibitor. Enhanced collateral growth correlated with improved CBF 1–4 days after pMCAO in the absence of Tie2-specific EphA4. Additional findings using inducible EphA4fl/fl/VeCadERT2 mice further demonstrate that loss of EphA4 on ECs can enhance collateral remodeling as early as 1 day after pMCAO.

Finally, we show that inhibition of EphA4 using the KYL peptide inhibitor mimicked the enhanced collateral response we observed genetic deletion in EC-specific KO mice. Overall, these findings highlight EphA4 and the Angpt/Tie2 axis as an important target for collateral therapeutics in stroke.

**Eph receptor tyrosine kinases are widely known to control cell migration, proliferation, and survival in the CNS. Although ephrin/Eph molecules play critical roles in numerous biological processes (37–39), the role of Eph/Ephrin signaling in cere-

(Figure 7E) compared with vehicle control (Figure 7D). This effect was observed in the MCA-ACA (50.61 ± 1.55 μm KYL vs. 42.35 ± 2.67 μm vehicle), MCA-PCA (49.15 ± 2.99 μm KYL vs. 35.90 ± 3.22 μm vehicle) and combined (49.88 ± 1.64 μm KYL vs. 39.13 ± 2.19 μm vehicle) arteriole branches (Figure 7A–C). A breakdown of collateral size showed a significant increase in the percentage of collaterals greater than 50 μm compared with vehicle (47% vs. 21%, respectively) (Figure 7F). We also found cultured WT ECs treated with KYL and an additional EphA4 blocking peptide, VTM-EEKK (36), showed increased p-Akt levels compared with vehicle-treated WT ECs, similar to expression in KO cells (Supplemental Figure 4, A and B). EC proliferation was increased by KYL treatment, in a dose-dependent manner, in WT ECs (Supplemental Figure 4, C–H). These findings are similar to the effects seen following genetic deletion of EphA4 and provide evidence for pharmacological targeting of this pathway for collateral therapeutics.

**Discussion**

Since their discovery by Heubner in 1874, leptomeningeal anastomoses have been implicated as critical determinants of injury severity. However, the cellular and molecular underpinnings of the arteriogenic response remain under investigation following ischemic stroke. Findings from the current study describe a mechanism that restricts outward growth and remodeling. Our results implicate the Tie2-EphA4 axis as a critical regulator of pial collateral remodeling following stroke. The presence of EphA4 on the endothelium acts as a negative cue within the collateral niche to restrict Tie2 receptor function via the p-Akt pathway, thereby restricting collateral outgrowth and remodeling. EphA4fl/fl/Tie2-Cre mice show increased p-Akt signaling, collateral remodeling, and tissue protection, which were attenuated in the presence of soluble Tie2 inhibitor. Enhanced collateral growth correlated with improved CBF 1–4 days after pMCAO in the absence of Tie2-specific EphA4. Additional findings using inducible EphA4fl/fl/VeCadERT2 mice further demonstrate that loss of EphA4 on ECs can enhance collateral remodeling as early as 1 day after pMCAO. Finally, we show that inhibition of EphA4 using the KYL peptide inhibitor mimicked the enhanced collateral response we observed genetic deletion in EC-specific KO mice. Overall, these findings highlight EphA4 and the Angpt/Tie2 axis as an important target for collateral therapeutics in stroke.

Eph receptor tyrosine kinases are widely known to control cell migration, proliferation, and survival in the CNS. Although ephrin/Eph molecules play critical roles in numerous biological processes (37–39), the role of Eph/Ephrin signaling in cere-
bral arteriogenesis has not been investigated. Previous studies have demonstrated that ephrinB2, an arterial-specific marker involved in arteriovenous specification (38, 40, 41), is induced following cyclic stretch and limits the migration of smooth muscle cells and transmigration of monocytes in vitro (42). EphA4 displays remarkable ligand-binding promiscuity and its binding complex with ephrinB2 has been described (43). While we cannot rule out associations with other A- or B-class ligands, it is plausible that EphA4-ephrinB2 interaction is induced within the collateral vessel wall following MCA occlusion, and that this region-specific partnership acts to prevent outward growth and remodeling. EphinB2 is located at the luminal and junctional endothelial cell surface where it associates with CD31 (44). Korff et al. demonstrated that quiescent smooth muscle–contacting ECs show uniform luminal expression of ephrinB2, which translocates to inter-endothelial cell junctions in a context-dependent manner. If this could occur under shear conditions within the collateral vessel wall, then association with and activation of EC-specific EphA4 forward receptor signaling may result in Tie2/p-Akt pathway suppression during remodeling. Further studies evaluating ephinB2<sup>-/-</sup> or ephinB2<sup>-/+</sup> mice could provide additional insight. Last, we showed that cultured EC treatment and in vivo infusion with KYL can increase p-Akt EC proliferation and enhance collateral outward growth, respectively. While these findings suggest that inhibiting EC-specific EphA4 on the collateral vessel wall may mediate these effects, we cannot rule out the possibility that systemic delivery of KYL may also regulate EphA4 activation on peripheral immune cells, which could contribute to these effects.

Our findings show that EphA4-Tie2 receptor crosstalk plays a critical role in pial collateral remodeling after stroke. Angiopoietin ligands of the Tie2 receptor are known regulators of arteriogenesis, which have been shown to affect blood flow recovery in ischemia (32, 45, 46). Although previous studies demonstrate these effects in non-CNS ischemic conditions, no studies have been conducted to assess the functional relevance of Tie2 signaling in the cerebrovascular collateral network after stroke. In particular, Angpt2 has been found to improve blood flow and arteriogenesis in hindlimb ischemia (32). Our studies revealed a significant reduction in Angpt2 and no change in Angpt-1 protein expression in the ipsilateral cortex of WT mice 1 day after pMCAO. Angpt2 levels were maintained in KO mice alongside increased collateral growth, suggesting that heightened Tie2 activation in the absence of EphA4 can accelerate collateral remodeling at this early time point. Indeed, blockade of the Tie2 receptor restored the size of KO pial collaterals to WT levels while having no effect in WT mice 1 day after pMCAO. Although we did not evaluate Angpt2 after 4 days, we postulate that the levels in WT mice would return to normal, similar to the p-Akt expression, concomitant with a substantial increase in WT collateral size as compared with the evaluation done at 1 day. Tie2 is expressed exclusively on the vascular endothelium and a subset of immune cells (47–49). Given that immune cells, such as monocytes, can mediate collateral growth, we cannot rule out the possibility that Tie-specific deletion of EphA4 on immune cells contributes to these effects. Enhanced pial collateral growth in VeCadERT2/EphA4<sup>fl/fl</sup> mice, however, mimicked EphA4 deletion in Tie2-expressing cells, further confirming that the suppressive effects of EphA4 on pial collaterals is mediated by endothelial cell regulation. Future studies will begin to address the earliest changes that may occur within 24 hours in the absence of EphA4, including both active remodeling and immediate retrograde compensation. Together with extensive in vitro EC analysis of EphA4 expression and function, our data support the role of EC-derived EphA4 as a major inhibitor of pial collateral growth.

It remains unclear what mechanistic role Angpt2 plays in pial collateral growth in EphA4<sup>fl/fl</sup>/Tie2-Cre mice after pMCAO. Angl is an established agonist of Tie2 activation, whereas Ang2 is a competitive inhibitor, although this has been challenged to be cell-type and context dependent (49). For example, at high or sustained concentrations, Angpt2 can stimulate Tie2 on ECs (50, 51), and acts as an agonist alongside Ang1 in the presence of TNF (52). Moreover, Tie2 interaction with Tie1 or VE-PTP receptors may further regulate the sensitivity of Tie2 to its ligands (53–55). The expression of these receptors has yet to be evaluated in the collateral vessel niche following occlusion. Our findings reveal that pMCAO induces an acute loss of Angpt2 expression which is mediated by EphA4 signaling and may prevent early induction of pial collateral remodeling. While these findings were observed in whole cortex samples, Tie2 and Angpt2 are predominately expressed by ECs. We cannot rule out the possible contribution of Tie2 and Angpt2 expression from infiltrating immune cells, but our in vitro findings provide strong support for the role of EphA4 in suppressing Tie2/Angpt2 signaling via p-Akt signaling directly in ECs. Given the importance of collateral growth in maintaining blood flow to the vulnerable penumbra region prior to thrombectomy (56), strategies that target the EphA4/Angpt2 discord to accelerate this process may help alleviate neural tissue damage and dysfunction.

The current study expands our knowledge of the wide net that Eph receptors cast on cellular function and provides key mechanistic insight into the growth constraints that limit the unique adaptive response of cerebral collateral vessels. To date, it remains unclear why some stroke patients display high collateral function after occlusion, while others do not. Understanding the mechanism(s) that regulate and importantly restrict this process will be crucial for devising approaches to predict collateral engagement while improving collateral health and neurological outcome in patients with ischemic stroke.

**Methods**

**Animals**

All rodents were bred and housed in an AAALAC-accredited, virus/antigen-free facility with a 12-hour light-dark cycle. Food and water were provided ad libitum. EphA4<sup>fl/fl</sup> and Tie2-Cre mice (catalog 012916 and catalog 008863, respectively, Jackson Laboratory) as well as VeCadERT2 mice (a gift from John Chappell, Fralin Biomedical Research Institute, Virginia Tech, Roanoke, Virginia) were backcrossed 10 generations on the CD1 background and crossbred until the desired experimental male mice at 8–10 weeks of age were generated. Male 8- to 10-week-old CD1 mice (Charles River) were used for peptide studies. All mice were coded at the time of surgery for double-blinded experimentation.
Surgical procedures and treatments
Ischemic stroke was induced by pMCAO as previously described (28). Briefly, 8- to 12-week-old male mice were injected with analgesic Buprenorphine-SR (0.15 mg/kg, ZooPharm) followed by induction of anesthesia using 2% isoflurane-30% oxygen. An incision was made and skull thinned to expose and cauterize the main and 2 distal branches of the left MCA. Sham controls received identical procedures without ligation. For Tie2-Fc study, immediately following pMCAO, mice were administered either 5 mg/kg of soluble Tie2-Fc or 2.5 mg/kg soluble human Fc-control via tail vein injection, then euthanized at 24 hours. Epha4 blocking peptide, KYLFPWPVLSL, was implanted in adult male CD1 mice subcutaneously via mini-osmotic pumps (Alzet, Inc; flow rate 0.5 μL/hour) at 10 mg/kg/day or saline vehicle immediately following pMCAO. Osmotic pumps were loaded and pre-incubated in sterile saline overnight at 37°C to prime the pumps. Mice were euthanized by vessel painting 4 days after pMCAO.

Vessel painting and collateral quantification
Vessel painting was performed as previously described (27, 57). Briefly, mice were injected with heparin (2000 U/kg) and sodium picosulphide (SNP, 0.75 mg/kg) 5 minutes prior to euthanization, using an overdose of isoflurane. When breathing stopped, mice were perfused with 10 mL of 1× PBS containing 20 U/mL heparin to flush blood from the vascular system, then a mixture of 10 mL DiI (0.01 mg/mL, Invitrogen) and 50 mL of 4% cold paraformaldehyde (PFA). Fixed brains were imaged at x4 magnification on an upright fluorescence microscope (BX-51, Olympus America) or inverted Zeiss 880 confocal microscope. Images were imported into ImageJ (NIH) for quantification of the number and diameter of inter-collaterals, as described (28). Similarly, images were assessed using ImageJ to quantify the number of PCNA+/VP+ cells within the collateral vessel walls from maximum Z-projected images using the cell-counting tool.

Infarct volume
Fresh frozen brains were embedded in OCT, snap frozen, and serial cryo-sectioned. Volume assessment (mm3) was assessed by using the Cavalieri Estimator from nonbiased Stereolevel software (MicroBrightField) as previously described (58). Briefly, 6 serial coronal sections were then stained with 0.2% cresyl violet solution (Electron Microscopy Science) and the infarcted area was identified by loss of Nissl staining and pyknotic neurons. Volume analysis was performed by estimating the area of tissue loss in the ipsilateral cortical hemisphere using six 30-μm serial coronal sections. A 100 μm–spaced grid was placed over the ipsilateral hemisphere in the Cavalieri probe and the infarcted area was scored.

Immunohistochemistry of cortical whole mounts
Cortical whole mounts were dissected and placed in 1X PBS overnight as previously described (28). Briefly, whole mounts were blocked in 2% fish gelatin (Sigma-Aldrich) with 0.1% Triton X-100 and incubated overnight in mouse anti–smooth muscle actin (SMA) (1:1000; Abcam, ab7817) at 4°C. Whole mounts were washed then incubated with anti-mouse Alexa Fluor 488-conjugated secondary antibody (Thermo Fisher Scientific) washed then imaged on Zeiss 880 confocal microscope (Carl-Zeiss). For PCNA staining, whole mounts were treated as previously described (59).

Table 1. qPCR primer information

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence (5′–3′)</th>
<th>Fw</th>
<th>Rv</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angpt2</td>
<td>Fw: GGAAGACAGATTGTTGACAG</td>
<td>Rv: TTTTGCTCCTAGCAGTA</td>
<td></td>
</tr>
<tr>
<td>Gapdh</td>
<td>Fw: CGTTTGCAAGAAAAGCTTGCAT</td>
<td>Rv: TCCTAGGGGGCGCTTGCAT</td>
<td></td>
</tr>
<tr>
<td>Tie2</td>
<td>Fw: AAATGACCTCTTGGAACCCGA</td>
<td>Rv: GTCAAGGGTGAAGCTCGTG</td>
<td></td>
</tr>
<tr>
<td>Eph4</td>
<td>Fw: AAAATCACTGCTGGGACCATC</td>
<td>Rv: TCCCTGAAAGAGGCTTCAAAT</td>
<td></td>
</tr>
<tr>
<td>Vegadherin</td>
<td>Fw: AGAAAGCAACACTCAATCTCACA</td>
<td>Rv: AACTGACCACTTGAACGCTTG</td>
<td></td>
</tr>
<tr>
<td>NeuN</td>
<td>Fw: CACTCTTGTGCTGTTCC</td>
<td>Rv: CTCCTGTGGCTGATCTG</td>
<td></td>
</tr>
<tr>
<td>GFAP</td>
<td>Fw: ACACTTAAACTCAAGAGAGAG</td>
<td>Rv: GATAGTCGCTTGCCTG</td>
<td></td>
</tr>
<tr>
<td>Cx32r1</td>
<td>Fw: GTCAAGTCGAGCCTGACTCTG</td>
<td>Rv: AATTAACAGCTTCACAGAAT</td>
<td></td>
</tr>
</tbody>
</table>

Western blot analysis
Ipsilateral cortical tissue or cell lysate from culture was homogenized in RIPA buffer as previously described (27), then 20-100 μg protein was separated by 10% SDS-PAGE. Membranes were blocked in TBS/0.1% Tween20 (TBST)/5% bovine serum albumin (BSA), then incubated in the following primary antibodies: phospho-Akt (catalog 4051, Cell Signaling Technology), pan Akt (catalog 4691, Cell Signaling Technology), angiopoietin 1 (catalog AF923, R&D Systems), and angiopoietin 2 (ab155106, Abcam) in blocking solution overnight. Membranes were then washed and incubated with secondary antibodies (anti-rabbit IgG Dylight conjugate 680 or anti-mouse IgG Dylight conjugate 800; Cell Signaling Technology), then imaged using LI-COR Odyssey Imaging Systems (LI-COR, Inc.). Band intensities were quantified using LI-COR’s Image Studio software.

Endothelial cell cultures
Primary brain-derived ECs were isolated, cultured, and purity characterized as previously described (27). Briefly, cells were cultured in defined media then treated with human Fc-control or soluble Tie2-Fc (Sino Biologics) diluted in EC base media (Cell Biologics Inc.) without growth factors for 24 hours. Protein was isolated using RIPA buffer for Western blot analysis of p-Akt expression. Additionally, for proliferation assays, 10 μM BrdU was added for 1 hour in the Tie2-Fc or Fc-control wells. Cells were then fixed and subjected to immunohistochemistry using anti-BrdU (1:100, Abcam). Images were taken on an Olympus BX-51 at ×10. The number of total cells and the number of BrdU-positive cells were counted using DAPI counterstain and quantified using ImageJ. For stimulation experiments, 300,000 cells were plated in 6-well plates containing growth medium in the presence or absence of 1 μg/mL LPS or following exposure to 30 and 50 dyne/cm² using an orbital shaker. RNA was extracted 4 and 24 hours after stimulation. For peptide inhibitor studies, 15,000 cells were plated in each well of a 96-well plate containing serum-free media treated with either VTM-EEEK, VTA-EEEK, KYL, or water (vehicle control) at 75, 250, or 500 μM. BrdU (Sigma-Aldrich, 10 μM) was added, and 24 hours later cells were fixed for immunohistochemistry using 1:1000, rat anti-BrdU.
Quantitative real-time PCR

Total RNA from cells isolated according to manufactures instructions using TRIzol reagent (Ambion) per the manufacturer’s instructions. RNA was quantified by absorbance with spectrophotometer ND-1000 (NanoDrop). cDNA was made with the iScript cDNA synthesis kit (BioRad) per the manufacturer’s specifications. For qRT-PCR analysis, 50 ng cDNA per reaction was amplified with iTaq Universal SyBR Green Universal (BioRad). Expression changes were calculated using ΔCq values with reference to Gapdh internal control. Relative expression was calculated then normalized to untreated WT samples. All primer efficiencies ranged from 87%–113% (Table 1).

Behavioral testing

All animal behaviors were performed as previously described for pMCAO (28).

Rotarod. Mice were pretrained for 4 consecutive days prior to pMCAO or sham injury at 10 rpm and an acceleration of 0.1 rpm per second over 10 minutes. A baseline was collected on the fourth day, then tested 3, 7, and 14 days after injury.

Neurological severity scoring (NSS). Sensorimotor deficits were tested before injury and 3 to 14 days after injury. NSS is a composite of motor, sensory (visual, tactile, and proprioceptive), reflex, and balance tests. Function was graded on a scale of 0 to 14 (normal = 0; maximal deficit = 14), where 1 point is awarded for the inability to perform the task.

Novel object recognition. Cognitive and spatial deficits were tested using NOR. Briefly, mice were introduced to 2 identical objects on day 1 and then one of the objects was replaced with a new object the following day (test day) in a 40 cm² arena. Time of exploration of the old and new object was recorded over 5 minutes. Preference of object was calculated as a ratio of exploration time of the specific object to the total time of exploration.

Cerebral blood flow

CBF was assessed as previously described (28). Briefly, CBF was assessed before, 5 minutes, and 1 to 4 days after injury using the Moor LDII-HIR Laser Doppler and Moor Software Version 5.3 (Moor Instruments). Briefly, mice were anesthetized with 2% isoflurane-30% O₂ and CBF, in PFUs, was scanned using a 2.5 cm × 2.5 cm scanning area. Tissue perfusion was quantified using the same standard region of interest (ROI) for every sample, representing the same area of the left hemisphere or side of injury and represented as a ratio of post-PFUs relative to each individual animal’s preinjury scan.

Statistical analysis

Data were graphed using GraphPad Prism, version 7 (GraphPad Software, Inc.). Student’s 2-tailed t test was used for comparison of 2 experimental groups. Multiple comparisons were done using 1-way or 2-way ANOVA and repeated measures where appropriate followed by Bonferroni’s post hoc test. Changes were identified as significant at P less than 0.05. Mean values were reported together with SEM. An experimenter blinded to the conditions performed all quantifications.

Study approval. All procedures were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals, and were approved by the Virginia Tech IACUC (15-063 and 18-088).

Author contributions

BO, YQ, and XW performed research and analyzed data. BO, JBM, and MHT wrote and edited the paper, designed the research, and contributed reagents/analytic tools. WAM, MC, JC, and AH performed research and analyzed data.

Acknowledgments

We recognize the Institute for Critical Technology and Science, Regenerative Medicine Interdisciplinary graduate education program (IGEP), Center for Engineered Health, and Initiative for Maximizing Student Development (5R25GM072767-12). We thank Jennifer Munson and Chase Cornelison for their assistance with shear stress induction and John Chappell for the gift of VcCadherin-CreERT2 mice. This work was supported by the National Institute of Neurological Disorders and Stroke of the NIH through grants R15NS081623 (to MHT), R01NS112541 (to MHT), and F31NS095719-01A1 (to BO).

Address correspondence to: Michelle H. Theus, Department of Biomedical Sciences and Pathobiology, College of Veterinary Medicine, Virginia Tech, 970 Washington Street SW (MC0910), Blacksburg, Virginia 24061, USA. Phone: 540.231.0909; Email: mtheus@vt.edu.